Evidence map›Paper›PMID 42653851›Full record

ArticleMolecules (Basel, Switzerland)2026

Apigenin Derivatives Alleviate OVA-Induced Oxidative Stress in Bronchial Asthma: A Structure-Activity Relationship Study.

Chenliang Li, Lijin Xiao, Wei Wu, Lingyang Kong, Shuyuan Yue, Zhijie Zhan, Jiao Xu, Wei Ma

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chenliang LiSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.ORCID 0009-0009-7608-6705
Lijin XiaoSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Wei WuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Lingyang KongSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Shuyuan YueSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Zhijie ZhanSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Jiao XuSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.
Wei MaSchool of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150040, China.

Funding

Heilongjiang Provincial Health Commission of China 20251313050489New Round of Heilongjiang "Double First-Class" Discipline Collaborative Innovation Achievement Project (2023) LJGXCG2023-058
6 · The paper itself

Abstract

Apigenin (API) is a flavonoid compound widely distributed in nature. The global prevalence of asthma is increasing year by year, influenced by various factors and difficult to cure completely, and new drugs and therapies are constantly emerging. Although API is a low-toxicity flavonoid compound, its poor water solubility and low bioavailability present limitations in the treatment of asthma. In this study, the structure of API was chemically modified by introducing acyl and alkyl groups while preserving its original structure. The structures were identified using FT-IR,

Indexed as

ApigeninAsthmaOvalbuminOxidative StressAnimalsAntioxidantsCytokinesDisease Models, AnimalLungMiceReactive Oxygen SpeciesStructure-Activity RelationshipSuperoxide DismutaseAntioxidantsApigeninCytokinesOvalbuminReactive Oxygen SpeciesSuperoxide Dismutaseapigeninbronchial asthmachemical synthesisoxidative stressstructure-activity relationship

Identifiers

PMID42653851
PMCPMC13515581

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.